A randomized trial of NVB plus DDP with versus without thalidomide in the treatment of advanced non small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 11, Issue 2, 2008, Pages 264-267

  He, Qiushan ^b   Yi, Tienan ^a   Luo, Bin ^b   Zhang, Xiaolin ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; NEVIRAPINE; THALIDOMIDE;

ANEMIA; ARTICLE; CANCER THERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FISHER EXACT TEST; HUMAN; KAPLAN MEIER METHOD; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 43649089160     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2008.02.019     Document Type: Article

References (4)

1. Hada M, Horiuchi T. A case report of chemotherapy with thalidomide, celeeoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer. No Shinkei Geka, 2005, 33 (10): 1021-1026.
2. Miller AA, Case D, Atkins JN, et al. Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer. J Thorac Oncol, 2006, 1(8): 832-836.
3. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer, 2005, 5(5): 397-405.
4. Srinivas S, Guardino AE. A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU Int, 2005, 96(4): 536-539.